ClinicalTrials.gg
CompletedNCT03226678Updated Dec 12, 2024Results posted

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

A Phase 2 interventional study of APL-2 in Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States — 4 open to participants now, 9 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · United States.

Enrollment
15th of 30
24 · median 24
Started
2017
the only one that year
Phase 2
14 of 31
1 open now
Registered
7th of 31
by date
Lead sponsor
1 of 31
Apellis Pharmaceuticals, Inc.

Among the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, this one is the 15th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2017, is one of 14 in phase 2, and was the 7th registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

4 of the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, or all of them as a file.
02

Study summary

This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).

03

Conditions studied

  • Warm Autoimmune Hemolytic Anemia
  • Cold Agglutinin Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age.
  2. Weight \< 125 Kg.
  3. Subjects must have a primary diagnosis of wAIHA or CAD defined by the presence of hemolytic anemia and positive DAT for wAIHA (IgG) or CAD (C3).
  4. \<11 g/dL.
  5. Signs of hemolysis with abnormal values by any of the hemolytic markers:

    1. Increased absolute reticulocyte count (above )
    2. Reduced haptoglobin (below LLN)
    3. Increased lactase dehydrogenase (LDH) (above ULN)
    4. Increased indirect (above ULN)
  6. Women of (WOCBP) (defined as any female who has experienced menarche and who is NOT permanently sterile or . Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause) must have a negative pregnancy test at screening and must agree to use protocol defined methods of for the duration of the study and 60 days after their last dose of study drug.
  7. Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study and 60 days after their last dose of study drug.
  8. Able to provide documentary evidence of the following vaccinations within 2 years prior to screening:

    1. Neisseria meningitides types A, C, W, Y and type B (administered as two separate vaccinations)
    2. Streptococcus pneumoniae (Pneumococcal conjugate vaccine and Pneumococcal polysaccharide vaccine 23 [PCV13 and/or PPSV23, respectively])
    3. Haemophilus influenzae Type B (Hib) vaccine

    Subjects that do not have documentary evidence must be willing to receive any missing vaccinations as outlined below:

    1. Neisseria meningitides types A, C, W, Y and type B must be administered prior to dosing on Day 1. A booster is administered after at least 8 weeks (Day 56; for both vaccinations).
    2. Streptococcus pneumoniae PCV13 must be administered prior to dosing on Day 1 (see Section 12.2 for details). A PPSV23 booster is administered after at least 8 weeks (Day 56)
    3. Haemophilus influenze Type B (Hib) must be administered prior to dosing on Day 1.
  9. Willing and able to give .
  10. Specific for wAIHA: from, did not respond or relapsed, or did not tolerate, at least one prior wAIHA treatment regimen (such as prednisone, rituximab).

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with rituximab within 90 days.
  2. Deficiency of iron, folic acid and vitamin B12 prior to treatment phase
  3. Abnormal liver function as indicated by a direct above normal level, and/or an or ALT level > 2x . Please note elevated indirect bilirubin due to hemolysis is not an exclusion criteria.
  4. Elevated bilirubin not due to active hemolysis. Any elevation of bilirubin >ULN will require Sponsor review and approval for subject enrollment into the trial.
  5. Active aggressive lymphoma requiring therapy or an active non-lymphatic malignant disease other than basal cell carcinoma or carcinoma in situ (CIS) of the cervix.
  6. Presence or suspicion of active bacterial or viral infection, in the opinion of the Investigator, at screening or severe recurrent bacterial infections.
  7. Participation in any other drug trial or exposure to other investigational agent, device, or procedure within 30 days prior to screening period.
  8. Pregnant, breast-feeding, or intending to conceive during the course of the study, including the Post-Treatment Phase.
  9. Inability to cooperate or any condition that, in the opinion of the investigator, could increase the subject's risk by participating in the study or confound the outcome of the study.
  10. Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or > Class 2 Angina Pectoris or Heart Failure Class >2
  11. > 470 ms
  12. PR > 280 ms
  13. Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    270mg or 360mg APL-2 administered subcutaneously daily (CAD)

    Drug: APL-2

  • Experimental
    270mg or 360mg APL-2 administered subcutaneously daily (wAIHA)

    Drug: APL-2

Interventions

  • DrugAPL-2

    Complement (C3) Inhibitor

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity

    TEAEs were defined as adverse events (AEs) that occurred after dosing on Day 1 and up to 56 days after the last dose of study drug. A treatment-related TEAE is defined as a TEAE with a relationship to study drug of probably, possibly, unlikely, or unrelated. A serious adverse event (SAE) is defined as any AE that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant incapacity or substantial disruption of ability to conduct normal life functions; was a congenital anomaly or birth defect. TEAEs were graded according to Common Terminology Criteria for Adverse Events v4.03 based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.

    Time frame: Part A:From first dose of study drug (Part A Day 1) up to 30days after last dose of study drug in Part A,approximately 366days Part B:From first dose of study drug (Part B Day 1) up to 56days after last dose of study drug in Part B,approximately 980days

Secondary outcomes

  1. Mean Change From Baseline in Hemoglobin at Weeks 48 and 132

    Hematology assessments of hemoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in hemoglobin results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

    Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132

  2. Number of Subjects Who Received Red Blood Cell (RBC) Transfusions

    The number of on-study RBC transfusions were monitored throughout the treatment period.

    Time frame: From Day 1 up to Week 132

  3. Mean Change From Baseline in Absolute Reticulocyte Count (ARC) at Weeks 48 and 132

    Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in ARC results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

    Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132

  4. Mean Change From Baseline in Lactate Dehydrogenase (LDH) at Weeks 48 and 132

    Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in LDH results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

    Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132

  5. Mean Change From Baseline in Haptoglobin at Weeks 48 and 132

    Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in haptoglobin results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

    Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132

  6. Mean Change From Baseline in Indirect Bilirubin at Weeks 48 and 132

    Serum chemistry assessments of indirect bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in indirect bilirubin results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

    Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132

  7. Maximum Observed Trough Serum Concentration (Ctrough,Max) of Pegcetacoplan

    Blood samples were collected for the assessment of Ctrough,max of pegcetacoplan.

    Time frame: Pre-dose and 4 hours postdose on Day 1; pre-dose on Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 36, 40, 48, 60, 72, 84, 96, 108, 120 and 132

  8. Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 48 and 132

    The FACIT-Fatigue Scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). There are 13 statements with the total score ranging from 0 to 52 and higher scores indicating better quality of life. Mean change from baseline in FACIT-Fatigue score results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

    Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132

  9. Mean Change From Baseline in Linear Analog Scale Assessment (LASA) Score at Weeks 48 and 132

    The LASA consists of 5 single statements asking subjects to rate their perceived level of functioning. Specific domains include physical well-being (fatigue, activity level), emotional well-being (depression, anxiety, stress), spiritual well-being (sense of meaning), and intellectual well-being (ability to think clearly and concentrate). An item for overall quality of life is also included. Each domain scale range from 0 to 10. Where, 0 = as bad as it can be and 10 = as good as it can be. The total score ranging from 0 to 50 and higher scores indicating better quality of life. Mean change from baseline in LASA score results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

    Time frame: Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132

07

Results

Posted Dec 12, 2024

Participant flow

This Phase 2, prospective pilot study was conducted at 12 sites in Brazil and United States of America in subjects with primary diagnosis of warm antibody autoimmune hemolytic anemia (wAIHA) or cold agglutinin disease (CAD) in parallel between 27 March 2018 and 12 September 2022.

Part A (Core Study Phase)
Participant flow — Part A (Core Study Phase)
MilestonePart A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
Started567600
Completed335500
Not completed232100
Withdrew: Adverse event010000
Withdrew: Death001000
Withdrew: Lack of efficacy010000
Withdrew: Non-compliance with study drug001000
Withdrew: Withdrawal by subject000100
Withdrew: Withdrew, per investigator210000
Part B (Long-Term Extension Phase)
Participant flow — Part B (Long-Term Extension Phase)
MilestonePart A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
Started000059
Completed000000
Not completed000059
Withdrew: Adverse event000021
Withdrew: Death000001
Withdrew: Non-compliance with study drug000001
Withdrew: Study terminated by sponsor000035
Withdrew: Withdrew, per sponsor000001

Outcome measures

PrimaryNumber of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity

TEAEs were defined as adverse events (AEs) that occurred after dosing on Day 1 and up to 56 days after the last dose of study drug. A treatment-related TEAE is defined as a TEAE with a relationship to study drug of probably, possibly, unlikely, or unrelated. A serious adverse event (SAE) is defined as any AE that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant incapacity or substantial disruption of ability to conduct normal life functions; was a congenital anomaly or birth defect. TEAEs were graded according to Common Terminology Criteria for Adverse Events v4.03 based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.

Time frame:
Part A:From first dose of study drug (Part A Day 1) up to 30days after last dose of study drug in Part A,approximately 366days Part B:From first dose of study drug (Part B Day 1) up to 56days after last dose of study drug in Part B,approximately 980days
Reported as:
Count of participants · Participants
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity
ParticipantsPart A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
All TEAEs557659
Treatment related TEAEs445445
Serious AEs323226
TEAEs leading to study drug discontinuation121122
TEAEs leading to death001001
TEAEs with mild intensity210011
TEAEs with moderate intensity023332
TEAEs with severe intensity323214
TEAEs with life threatening intensity000101
SecondaryMean Change From Baseline in Hemoglobin at Weeks 48 and 132

Hematology assessments of hemoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in hemoglobin results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

Time frame:
Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Reported as:
Mean · gram per deciliter (g/dL)
Mean Change From Baseline in Hemoglobin at Weeks 48 and 132
gram per deciliter (g/dL)Part A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
Week 480.38 ± 2.3471.93 ± 0.8741.62 ± 1.5222.63 ± 1.694——
Week 132————0.18 ± 0.626-0.20 ± 2.029
SecondaryNumber of Subjects Who Received Red Blood Cell (RBC) Transfusions

The number of on-study RBC transfusions were monitored throughout the treatment period.

Time frame:
From Day 1 up to Week 132
Reported as:
Count of participants · Participants
Number of Subjects Who Received Red Blood Cell (RBC) Transfusions
ParticipantsPart A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
Number of Subjects Who Received Red Blood Cell (RBC) Transfusions222103
SecondaryMean Change From Baseline in Absolute Reticulocyte Count (ARC) at Weeks 48 and 132

Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in ARC results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

Time frame:
Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Reported as:
Mean · 10^9 cells/liter (L)
Mean Change From Baseline in Absolute Reticulocyte Count (ARC) at Weeks 48 and 132
10^9 cells/liter (L)Part A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
Week 48-145.050 ± 90.4181-130.187 ± 70.4638-73.515 ± 73.1983-84.064 ± 46.0655——
Week 132————11.485 ± 4.978781.585 ± 83.4790
SecondaryMean Change From Baseline in Lactate Dehydrogenase (LDH) at Weeks 48 and 132

Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in LDH results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

Time frame:
Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Reported as:
Mean · international units/L
Mean Change From Baseline in Lactate Dehydrogenase (LDH) at Weeks 48 and 132
international units/LPart A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
Week 48-51.8 ± 39.08-169.7 ± 212.89-475.8 ± 842.43-77.8 ± 73.30——
Week 132————1.78 ± 46.35735.18 ± 82.727
SecondaryMean Change From Baseline in Haptoglobin at Weeks 48 and 132

Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in haptoglobin results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

Time frame:
Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Reported as:
Mean · g/L
Mean Change From Baseline in Haptoglobin at Weeks 48 and 132
g/LPart A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
Week 480.715 ± 0.76220.747 ± 0.73060.528 ± 0.49610.172 ± 0.3404——
Week 132————-0.270 ± 0.6364-0.335 ± 0.1323
SecondaryMean Change From Baseline in Indirect Bilirubin at Weeks 48 and 132

Serum chemistry assessments of indirect bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the different parts of the treatment period. Mean change from baseline in indirect bilirubin results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

Time frame:
Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Reported as:
Mean · micromole/L
Mean Change From Baseline in Indirect Bilirubin at Weeks 48 and 132
micromole/LPart A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
Week 48-10.723 ± 4.2167-9.697 ± 5.2220-15.879 ± 15.1038-17.981 ± 7.0978——
Week 132————0.195 ± 0.27644.095 ± 8.7678
SecondaryMaximum Observed Trough Serum Concentration (Ctrough,Max) of Pegcetacoplan

Blood samples were collected for the assessment of Ctrough,max of pegcetacoplan.

Time frame:
Pre-dose and 4 hours postdose on Day 1; pre-dose on Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 36, 40, 48, 60, 72, 84, 96, 108, 120 and 132
Reported as:
Mean · microgram per milliliter
Maximum Observed Trough Serum Concentration (Ctrough,Max) of Pegcetacoplan
microgram per milliliterPart A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
Maximum Observed Trough Serum Concentration (Ctrough,Max) of Pegcetacoplan629.6 ± 206.66679.7 ± 303.76661.6 ± 192.24807.8 ± 105.12813.6 ± 260.08795.6 ± 204.90
SecondaryMean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 48 and 132

The FACIT-Fatigue Scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). There are 13 statements with the total score ranging from 0 to 52 and higher scores indicating better quality of life. Mean change from baseline in FACIT-Fatigue score results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

Time frame:
Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Reported as:
Mean · score on a scale
Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 48 and 132
score on a scalePart A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
Week 48-3.8 ± 8.3810.7 ± 5.510.5 ± 16.339.0 ± 7.07——
Week 132————-1.0 ± 1.412.8 ± 7.23
SecondaryMean Change From Baseline in Linear Analog Scale Assessment (LASA) Score at Weeks 48 and 132

The LASA consists of 5 single statements asking subjects to rate their perceived level of functioning. Specific domains include physical well-being (fatigue, activity level), emotional well-being (depression, anxiety, stress), spiritual well-being (sense of meaning), and intellectual well-being (ability to think clearly and concentrate). An item for overall quality of life is also included. Each domain scale range from 0 to 10. Where, 0 = as bad as it can be and 10 = as good as it can be. The total score ranging from 0 to 50 and higher scores indicating better quality of life. Mean change from baseline in LASA score results were summarized from Part A baseline for Part A reporting groups and from Part B baseline for Part B reporting groups.

Time frame:
Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132
Reported as:
Mean · score on a scale
Mean Change From Baseline in Linear Analog Scale Assessment (LASA) Score at Weeks 48 and 132
score on a scalePart A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
Week 480.0 ± 2.451.3 ± 4.040.8 ± 1.721.0 ± 1.15——
Week 132————0.0 ± 0.000.5 ± 1.73

Adverse events

Collected over Part A: TEAE data is reported from first dose of study drug (Day 1 of Part A) up to 30 days after the last dose of study drug in Part A, approximately 366 days. Part B: TEAE data is reported from first dose of study drug (Day 1 of Part B) up to 56 days after the last dose of study drug in Part B, approximately 980 days. All-cause mortality: From first dose of study drug (Day 1) up to end of the study, approximately 1346 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Cohort 1 wAIHA - 270 mg0/5 (0%)3/5 (60%)5/5 (100%)
Part A: Cohort 1 wAIHA - 360 mg0/6 (0%)2/6 (33.3%)5/6 (83.3%)
Part A: Cohort 2 CAD - 270 mg1/7 (14.3%)3/7 (42.9%)7/7 (100%)
Part A: Cohort 2 CAD - 360 mg0/6 (0%)2/6 (33.3%)6/6 (100%)
Part B: Cohort 1 wAIHA - 1080 mg0/5 (0%)2/5 (40%)5/5 (100%)
Part B: Cohort 2 CAD - 1080 mg1/9 (11.1%)6/9 (66.7%)9/9 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPart A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
Autoimmune haemolytic anaemiaBlood and lymphatic system disorders2/50/61/70/60/50/9
Haemoglobin decreasedInvestigations0/50/60/70/61/51/9
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/50/60/70/61/50/9
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/50/60/70/60/50/9
HaemolysisBlood and lymphatic system disorders0/51/60/70/60/50/9
Blood calcium increasedInvestigations0/50/60/71/60/50/9
Blood creatinine increasedInvestigations0/50/60/71/60/50/9
DyspnoeaRespiratory, thoracic and mediastinal disorders0/50/60/71/60/50/9
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/51/60/70/60/50/9
Cholecystitis acuteHepatobiliary disorders0/50/61/70/60/50/9
Most frequent other events
Showing 10 of 183
Most frequent other events
EventPart A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgPart B: Cohort 1 wAIHA - 1080 mgPart B: Cohort 2 CAD - 1080 mg
HeadacheNervous system disorders0/50/63/71/63/50/9
CoughRespiratory, thoracic and mediastinal disorders3/50/60/72/61/52/9
DiarrhoeaGastrointestinal disorders2/50/64/71/62/50/9
ContusionInjury, poisoning and procedural complications0/50/60/73/61/52/9
DizzinessNervous system disorders1/50/60/73/60/53/9
HypertensionVascular disorders1/50/61/73/60/51/9
Weight decreasedInvestigations0/50/60/70/60/54/9
Vitamin B12 deficiencyMetabolism and nutrition disorders1/51/63/71/60/50/9
Autoimmune haemolytic anaemiaBlood and lymphatic system disorders0/50/60/70/62/50/9
NauseaGastrointestinal disorders2/50/62/72/62/51/9

Baseline characteristics

The Safety set included all subjects who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Part A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgTotal
Mean58.6 ± 17.5754.3 ± 22.1268.9 ± 8.5175.7 ± 7.5364.8 ± 16.25
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgTotal
Female334515
Male23319
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgTotal
Black Or African American00011
White567523
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Cohort 1 wAIHA - 270 mgPart A: Cohort 1 wAIHA - 360 mgPart A: Cohort 2 CAD - 270 mgPart A: Cohort 2 CAD - 360 mgTotal
Hispanic Or Latino33118
Not Hispanic Or Latino236516
08

Study locations

8 sites
  • American Institute of Research
    Whittier, California 90603, United States
  • Lakes Research
    Miami Lakes, Florida 33014, United States
  • Mid Florida Hematology Oncology
    Orange City, Florida 32763, United States
  • University of Iowa Hospitals
    Iowa City, Iowa 52242, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • East Carolina University
    Greenville, North Carolina 27834, United States
  • University of Tennessee Medical Center
    Knoxville, Tennessee 37920, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Sep 2022, 60 months.

Results were first posted in Dec 2024, 2 years 3 months after primary completion. A results delay was requested in Jul 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2017
First posted
Jul 24, 2017
StartActual
Aug 31, 2017
Primary completionActual
Sep 12, 2022
CompletionActual
Sep 12, 2022
Results delay requested
Jul 21, 2020
Results first posted
Dec 12, 2024
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03226678
Responsible party
Sponsor
First posted
Jul 24, 2017
Start date
Aug 31, 2017
Primary completion
Sep 12, 2022
Completion
Sep 12, 2022
Results posted
Dec 12, 2024
Last update
Dec 12, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion